Přeskočit na hlavní obsah

Příspěvky

Zobrazují se příspěvky z listopad, 2010

Ifosfamid

Charakteristika

alkylační cytostatikum ze skupiny oxazafosforinůlátka příbuzná cyklofosfamidu (CFA)je aktivován v játrech , oproti CFA je jaterní aktivace pomalejší je zhruba potřeba 4x vyšší dávky k dosažení  srovnatelného protinádorového účinkupři aktivaci ifosfamidu vzniká větší množství chloracetaldehidu- vyšší uroteliální a neurologické toxicityFarmakokinetika t1/2  5-6 hod ( při dávce nad 5000mg/m2 je t1/2 13-14 hodu starších pacientů prodloužené vylučovánívylučování  57- 80% močíNežádoucí účinky uroteliální toxicita ( hemoragická cystitida, dysurie, fibróza močového měchýře)- podání vyžaduje aplikaci mesnyalopecienauzeadermatitis,hyperpigmentacezhoršení fce jater a ledvinreverzibní encefalopatie (dezorientace a zmatenost), halucinace, bolesti hlavy, méně často závratě, vzácně polyneuropatie, encefalopatie, epileptické paroxysmy, kómamyelosupresehyperurikémie, urátová nefropatieméně často nefrotoxicita, hepatotoxicita; vzácně stomatitida, kardiotoxicita, pneumonitida; riziko vzniku…

Moderate Physical Activity May Reduce Postmenopausal Breast Cancer Risk

Moderate Physical Activity May Reduce Postmenopausal Breast Cancer Risk

... The association with total activity did not differ significantly between estrogen and progesterone receptor–positive and –negative tumors (P = .65 for heterogeneity)," the study authors write. "Our findings suggest that moderate physical activity, including brisk walking, may reduce postmenopausal breast cancer risk and that increases in activity after menopause may be beneficial."

Chemoradiation Improves Disease Control in Bladder Cancer

Chemoradiation Improves Disease Control in Bladder Cancer
...
Adding chemotherapy to radiation therapy caused 82% of people to be free of invasive bladder cancer 2 years after treatment," said study author Nicholas James, MD, professor of clinical oncology at the University of Birmingham, United Kingdom. "This compares with 68% who received radiation alone."

Large Meta-Analysis Finds Statin Use Cuts Colorectal Cancer Risk by 10% - OncologySTAT

Large Meta-Analysis Finds Statin Use Cuts Colorectal Cancer Risk by 10% - OncologySTAT

Statin use was associated with a moderate but significant 10% reduction in risk of colorectal cancer, based on a meta-analysis of 24 studies, investigators reported at the annual scientific meeting of the American College of Gastroenterology.

Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO

Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO
.....

Do these data suggest that we should incorporate platinum agents into adjuvant or neoadjuvant therapy inBRCA1carriers? No. On the basis of currently available evidence, we cannot say that there is definitive evidence of a platinum benefit in triple-negative or evenBRCA1-associated breast cancer, nor can we say that there is adequate evidence to routinely incorporate platinum agents into adjuvant or neoadjuvant therapy for any identifiable subtype of breast cancer. What we can say is that this is a reasonable avenue to pursue in prospective trials, and we can feel reassured that the clinical evidence thus far fits with preclinical models. With the advent of rational approaches developed fromBRCA1-associated models, which we hope will be successfully applied to sporadic basal-like breast cancer, we will finally alter the prognostic landscape for patients with this disease.

Rioja Puente de La Fronteracustomer …